Pharmaceutical composition for treating degenerative brain disease, including glycine transporter as active ingredient
Provided is a pharmaceutical composition for treating a degenerative brain disease, including a glycine transporter as an active ingredient. A composition including, as an active ingredient, a glycine transporter protein, a fragment thereof or a nucleic acid molecule encoding the protein or the fragment thereof, a vector including the nucleic acid molecule, or a cell transformed with the vector including the nucleic acid molecule, according to an embodiment, not only can achieve excellent effect(s) of inhibiting amyloid-beta aggregation and/or degrading aggregated amyloid-beta, but also degrades tau protein (and/or inhibition of the aggregation thereof), inhibits the hyperphosphorylation of tau protein, and has excellent blood-brain barrier permeability, thus making it possible to successively act on brain tissues. Therefore, the composition can be effectively applied to the prevention and/or treatment of various degenerative brain diseases associated with amyloid-beta aggregation, tau protein aggregation, and/or hyperphosphorylated tau protein.
1 . A method of preventing, ameliorating or treating amyloid-beta aggregation-caused degenerative brain disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a vector comprising a nucleic acid molecule encoding a glycine transporter protein,
wherein the glycine transporter protein is glycine transporter-1 (GlyT1),
wherein the subject has a higher level or a higher risk of aggregation of amyloid-beta than normal individuals not having a degenerative brain disease, and
wherein the amyloid-beta aggregation-caused degenerative brain disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, mild cognitive impairment, cerebral amyloid angiopathy, amyloid stroke, senile dementia, and amyotrophic lateral sclerosis.
2 . The method of claim 1 , wherein the vector is any one selected from the group consisting of a plasmid vector, a cosmid vector, a bacteriophage vector, an adenoviral vector, a retroviral vector, and an adeno-associated viral vector.
3 . The method of claim 2 , wherein the adeno-associated viral vector is any one selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, and AAV11.
4 . The method of claim 1 , wherein the GlyT1 comprises an amino acid sequence encoded by a polynucleotide sequence of SEQ ID NO: 1.
5 . The method of claim 1 , wherein the aggregation of the amyloid-beta is caused by glycine.